Crizotinib
Orphan DrugFDA Approved
Description
Crizotinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets ALK and ROS1 kinases.
Indications & Therapeutic Use
ALK-positive non-small cell lung cancer, ROS1-positive non-small cell lung cancer
Linked Diseases:
hydrops fetalis
P56D015160
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Crizotinib
| Generic Name | Crizotinib |
| Brands | 1 brand available |
| Active Ingredient | Crizotinib |
| Drug Class | ALK-positive non-small cell lung cancer |
| Manufacturer | Pfizer |
| Dosage Forms | Capsule, 200mg |
| Medical Code | L01XE16 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00585195 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes